DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,504 filers reported holding DANAHER CORPORATION in Q4 2019. The put-call ratio across all filers is 1.66 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,688,000 | -26.2% | 5,753 | -17.2% | 0.60% | -19.9% |
| Q4 2021 | $2,286,000 | +8.0% | 6,948 | -0.0% | 0.75% | -1.4% |
| Q3 2021 | $2,116,000 | +13.2% | 6,950 | -0.3% | 0.76% | +14.3% |
| Q2 2021 | $1,870,000 | +12.3% | 6,970 | -5.8% | 0.67% | +3.9% |
| Q1 2021 | $1,665,000 | -4.9% | 7,398 | -6.2% | 0.64% | -7.9% |
| Q4 2020 | $1,751,000 | -1.1% | 7,883 | -4.1% | 0.70% | -13.7% |
| Q3 2020 | $1,771,000 | +21.5% | 8,223 | -0.2% | 0.81% | +11.7% |
| Q2 2020 | $1,458,000 | +27.8% | 8,243 | 0.0% | 0.72% | +2.3% |
| Q1 2020 | $1,141,000 | -10.4% | 8,243 | -0.7% | 0.71% | +12.7% |
| Q4 2019 | $1,274,000 | +5.3% | 8,303 | -0.9% | 0.63% | -5.4% |
| Q3 2019 | $1,210,000 | +1.1% | 8,378 | 0.0% | 0.66% | -0.9% |
| Q2 2019 | $1,197,000 | +7.5% | 8,378 | -0.6% | 0.67% | +8.6% |
| Q1 2019 | $1,113,000 | +24.6% | 8,428 | -2.7% | 0.62% | +10.6% |
| Q4 2018 | $893,000 | -5.1% | 8,660 | 0.0% | 0.56% | +13.2% |
| Q3 2018 | $941,000 | +10.1% | 8,660 | 0.0% | 0.49% | +20.5% |
| Q2 2018 | $855,000 | +0.8% | 8,660 | 0.0% | 0.41% | -2.6% |
| Q1 2018 | $848,000 | +3.2% | 8,660 | -2.3% | 0.42% | +7.4% |
| Q4 2017 | $822,000 | +8.2% | 8,860 | 0.0% | 0.39% | +2.9% |
| Q3 2017 | $760,000 | -18.5% | 8,860 | -19.9% | 0.38% | -2.3% |
| Q2 2017 | $933,000 | -1.5% | 11,060 | -0.1% | 0.39% | -3.0% |
| Q1 2017 | $947,000 | +6.0% | 11,070 | -3.5% | 0.40% | -1.0% |
| Q4 2016 | $893,000 | -0.7% | 11,470 | 0.0% | 0.41% | -3.1% |
| Q3 2016 | $899,000 | -22.4% | 11,470 | 0.0% | 0.42% | -22.1% |
| Q2 2016 | $1,158,000 | +6.4% | 11,470 | 0.0% | 0.54% | +2.1% |
| Q1 2016 | $1,088,000 | +2.2% | 11,470 | 0.0% | 0.53% | +1.3% |
| Q4 2015 | $1,065,000 | +9.0% | 11,470 | 0.0% | 0.52% | +2.2% |
| Q3 2015 | $977,000 | -0.5% | 11,470 | 0.0% | 0.51% | +6.9% |
| Q2 2015 | $982,000 | +0.8% | 11,470 | 0.0% | 0.48% | +1.9% |
| Q1 2015 | $974,000 | -5.3% | 11,470 | -4.3% | 0.47% | -1.5% |
| Q4 2014 | $1,028,000 | +11.9% | 11,990 | -0.8% | 0.47% | +7.5% |
| Q3 2014 | $919,000 | -3.8% | 12,090 | -0.3% | 0.44% | -2.4% |
| Q2 2014 | $955,000 | +4.4% | 12,130 | -0.6% | 0.45% | -1.3% |
| Q1 2014 | $915,000 | -2.9% | 12,205 | 0.0% | 0.46% | -4.0% |
| Q4 2013 | $942,000 | -1.9% | 12,205 | -11.9% | 0.48% | -12.5% |
| Q3 2013 | $960,000 | +4.5% | 13,850 | -4.6% | 0.54% | +4.4% |
| Q2 2013 | $919,000 | – | 14,515 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |